Barry Marshall

Prof. Barry Marshall

orcid

Research Focus & Metrics

Academic Career Length

43Years (1984-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 1984 in The Lancet
Verified
Journal Article
Closed access
BMBarry Marshall
Barry Marshall
JWJ.Robin Warren
J.Robin Warren

1 December 1988 in The Lancet
Verified
Journal Article
Closed access
BMBarry Marshall
Barry Marshall
JWJ.RObin Warren
J.RObin Warren
EBElizabethD. Blincow
ElizabethD. Blincow
MPMichael Phillips
Michael Phillips
CGC.STewart Goodwin
C.STewart Goodwin
CSChristopherR. Sanderson
ChristopherR. Sanderson

1 April 1986 in Journal of Clinical Pathology
Verified
Journal Article
Closed access
CGC S Goodwin
C S Goodwin
JAJ A Armstrong
J A Armstrong
BMBarry Marshall
Barry Marshall
Campylobacter pyloridis is a spiral bacterium which was seen by histopathologists several years before it was cultured in 1982 in Perth, Western Australia. It has unique cellular fatty acids, predominantly tetradecanoic acid and cis-11, 12 methylene octadecanoic acid. It also has a unique ultrastructure which is different from that of other campylobacters. C pyloridis possesses a powerful urease enzyme and produces large amounts of extracellular catalase. Both these features may be important virulence factors, allowing it to occupy a protected niche in the stomach below the mucus layer but above the gastric mucosa. Specific lesions are found in the gastric mucosa, and ultrastructural studies show the presence of adherence pedestals identical with those found with enteropathogenic Escherichia coli of the intestine. Histological examination of gastric biopsy tissue has shown that C pyloridis is strongly associated with active chronic gastritis, when polymorphonuclear leucocytes are present, and is not found on normal mucosa except when a biopsy specimen from elsewhere in the stomach shows active chronic gastritis. When patients with symptoms caused by gastritis are identified dual antibacterial treatment, combining the action of bismuth in the stomach with a systemic antibiotic, can eradicate C pyloridis, with remission of symptoms and restoration of normal epithelial morphology. Most peptic ulcers relapse after modern acid reducing treatment, and antibacterial treatment may be beneficial in preventing relapse.

1 September 1990 in Gastroenterology
Verified
Journal Article
Closed access
BMBarry Marshall
Barry Marshall
LBL.J. Barrett
L.J. Barrett
CPC. Prakash
C. Prakash
RMR.W. McCallum
R.W. McCallum
RGR.L. Guerrant
R.L. Guerrant

23 January 2009 in Science
Verified
Journal Article
Closed access
PDF file
YMYoshan Moodley
Yoshan Moodley
BLBodo Linz
Bodo Linz
Yoshio YamaokaYoshio Yamaoka
Yoshio Yamaoka
HWHelen M. Windsor
Helen M. Windsor
SBSebastien Breurec
Sebastien Breurec
MAMark Achtman
Mark Achtman
Two prehistoric migrations peopled the Pacific. One reached New Guinea and Australia, and a second, more recent, migration extended through Melanesia and from there to the Polynesian islands. These migrations were accompanied by two distinct populations of the specific human pathogen Helicobacter pylori , called hpSahul and hspMaori, respectively. hpSahul split from Asian populations of H. pylori 31,000 to 37,000 years ago, in concordance with archaeological history. The hpSahul populations in New Guinea and Australia have diverged sufficiently to indicate that they have remained isolated for the past 23,000 to 32,000 years. The second human expansion from Taiwan 5000 years ago dispersed one of several subgroups of the Austronesian language family along with one of several hspMaori clades into Melanesia and Polynesia, where both language and parasite have continued to diverge.

1 February 1988 in Journal of Clinical Pathology
Verified
Journal Article
Open access
PDF file
CGC S Goodwin
C S Goodwin
BMBarry Marshall
Barry Marshall
EBE D Blincow
E D Blincow
DWD H Wilson
D H Wilson
SBS Blackbourn
S Blackbourn
MPMichael Phillips
Michael Phillips
One hundred patients with duodenal ulceration and Campylobacter pylori in their stomach were entered into a double blind placebo controlled prospective study. Treatment schedules were cimetidine and placebo, or cimetidine and tinidazole, or colloidal bismuth subcitrate (CBS) and placebo, or CBS and tinidazole. Seventeen per cent of isolates of C pylori obtained at the first endoscopy were resistant to tinidazole and 70% of the second isolates from patients given cimetidine and tinidazole became tinidazole resistant. Suspensions of nitroimidazole sensitive cultures of C pylori showed that three of 22 isolates had a nitroimidazole resistant subpopulation. In patients who healed and remained free of C pylori after treatment ulcers recurred less often than in patients who healed but retained C pylori (23% v 73% over 12 months, p less than 0.001).